SAN DIEGO, February 11, 2020 – ProSciento, Inc., a clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, today announced the appointment of Michael Grimm, MD, PhD to its executive management team as Chief Medical Officer (CMO).
Dr. Michael Grimm is a drug development expert with deep scientific expertise in metabolic, cardiovascular and inflammatory diseases through his work in academia and the biopharmaceutical industry, including senior clinical development roles at AnaptysBio, MyoKardia, Receptos, Santarus and Amylin Pharmaceuticals.
“We are thrilled to have Michael Grimm join ProSciento as Chief Medical Officer. Michael is highly regarded in the industry for his scientific and business acumen and proven track record in guiding promising compounds from early stages of development through regulatory approval,” said Marcus Hompesch, MD, ProSciento CEO and Chairman of the Board. “His considerable experience leading drug development programs, in addition to his deep scientific expertise in metabolic research, make him an ideal addition to the ProSciento leadership team.”
Dr. Grimm’s leadership in drug development and clinical research spans nearly 20 years and includes key contributions to multiple FDA-approved drugs. Prior to his appointment as CMO at ProSciento, he served as Executive Director of Clinical Development for AnaptysBio, overseeing the development of etokimab for inflammatory respiratory and skin diseases and, before that, was Executive Director of Clinical Development for MyoKardia, responsible for the clinical development strategy and execution of the company’s lead drug candidate mavacamten, currently in phase 3 clinical trials. Prior to his role at MyoKardia, Dr. Grimm was Senior Director at Receptos and Clinical Development Lead for the early phase drug candidate RPC4046 (anti-IL-13 mAb) and Medical Director at Santarus for FDA-approved Ruconest (recombinant C1 esterase inhibitor) and UCERIS (budesonide). He was also Medical Director at Amylin Pharmaceuticals and the Clinical Development Physician for FDA-approved drugs Exenatide (GLP-1 receptor agonist) and Metreleptin (leptin analog).
Dr. Grimm earned his MD and PhD in pharmacology from the University of Hamburg, Germany. He then conducted postdoctoral research in cardiovascular research at the Brigham and Women’s Hospital in Boston; his residency in cardiology at the University Medical Center Schleswig-Holstein, Germany; and a fellowship in clinical pharmacology at the University Medical Center Hamburg, Germany. He is an author on more than 25 peer-reviewed medical journal publications.
His predecessor, Dr. Linda Morrow, who has overseen the company’s medical and scientific teams since 2009, announced her impending retirement in December. She will remain with ProSciento as a scientific consultant and board member. Her contributions to the field have included clinical development strategies and early phase research studies for many approved diabetes and related metabolic drugs and devices on the market today and co-authorship of more than 40 publications.
About ProSciento, Inc.
ProSciento is a leading specialized clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 300 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally. For more information, please visit www.nashpass.wpengine.com.
For business development inquiries, please contact:
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
For clinical trial enrollment inquires:
Tel: +1 (866) 308-7427